Diagnosis Is Beside the Point
Some of the thorniest problems in medicine that AI can improve have nothing to do…
Diagnosis Is Beside the Point
Some of the thorniest problems in medicine that AI can improve have nothing to do with diagnosis. They have to do with triage. The post Diagnosis Is Beside the Point appeared first on MedCity News.
Readers Are Pleading To Make American Healthcare Greater
Letters to the Editor is a periodic feature. We welcome all comments and will publish a selection. We edit for length and clarity and require full names. Not-So-Great Healthcare Why doesn’t world-class medicine produce world-class health? Hayat Norimine’s reporting gets at something that has bothered me for a long time about American healthcare (Priced Out: “As Health Insurance…
Four Red Flags and One Truth Amid the Peptide Hype
Experimental peptides have become darlings among influencers, chiropractors, and doctors focused on longevity, antiaging, or “body optimization,” even though the FDA hasn’t approved them for safety or effectiveness. Health secretary Robert F. Kennedy Jr. and other leaders of the Make America Healthy Again movement have pushed to make unproven peptides more accessible — and they’ve…
GOP Focuses on Fraud, Seeking To Redirect Voters’ Ire Over Healthcare Costs
Heading into the midterm elections, high healthcare costs rank among voters’ biggest concerns. But lately, there’s a twist giving the issue new momentum on campaign agendas: a focus on fraud in government health programs. The administration of President Donald Trump has used claims of widespread wrongdoing to justify investigations, suspensions of billions of dollars in…
A Regulatory Blind Spot Hiding in Plain Sight
By JUSTIN MCKAY When I’m brought back into the diagnostic area, one of the first things I see is a lead apron, well-worn and folded into itself, about ready to slide off the table where it was absentmindedly placed. For many people, this sight would not be startling, but I know firsthand the life-threatening dangers…
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But Vertex Pharmaceuticals could also compete with a drug candidate from a recent acquisition. The post Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder appeared first on MedCity…
Allswell Raises $7M to Grow LGBTQ+ Behavioral Health Platform
Allswell’s seed round was led by Rethink Impact, and included participation from Magnify Ventures, Ulu Ventures and Hopelab Ventures, joining existing investors Techstars and Amboy Street Ventures. The post Allswell Raises $7M to Grow LGBTQ+ Behavioral Health Platform appeared first on MedCity News.
The Antibiotics Exist —The System Cannot Deliver Them
This is not a discovery problem. It is a market entry and access problem, and it is far more tractable than the pipeline crisis we spend most of our attention on. The post The Antibiotics Exist —The System Cannot Deliver Them appeared first on MedCity News.
Exercise is Prescribed Like Advice When It Should Be Delivered Like Treatment
Health care routinely recommends movement without providing assessment, dosage, progression, and follow-up that turn good advice into usable care. The post Exercise is Prescribed Like Advice When It Should Be Delivered Like Treatment appeared first on MedCity News.
UPMC Enterprises Invests in VeloSource to Expand AI-Enabled Clinician Staffing Platform
UPMC Enterprises is making a strategic investment in VeloSource with plans to further develop its AI-enabled staffing management platform. The post UPMC Enterprises Invests in VeloSource to Expand AI-Enabled Clinician Staffing Platform appeared first on MedCity News.
